Time to rethink haemoglobin threshold guidelines in sickle cell disease-Reference-Cited by-同舟云学术

Time to rethink haemoglobin threshold guidelines in sickle cell disease

Published:2021-06-15 Issue:4 Volume:195 Page:518-522
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Ballas Samir K.¹^ORCID,Kuypers Frans A.²,Gordeuk Victor R.³^ORCID,Hankins Jane S.⁴^ORCID,Thompson Alexis A.⁵,Vichinsky Elliott⁶

Affiliation:

1. Department of Medicine Cardeza Foundation for Hematologic Research Sidney Kimmel Medical College Thomas Jefferson University Philadelphia PAUSA

2. Children's Hospital Oakland Research Institute Oakland CAUSA

3. University of Illinois Chicago ILUSA

4. Department of Hematology St. Jude Children's Research Hospital Memphis TNUSA

5. Ann & Robert H. Lurie Children's Hospital of Chicago Chicago ILUSA

6. UCSF Benioff Children's Hospital Oakland Oakland CA USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17578

Reference34 articles.

1. National Heart Lung and Blood Institute.Evidence‐based management of sickle cell disease. Expert Panel Report.2014.Bethesda MD:National Institutes of Health pp.1–142.

2. Red Cell Exchange in Sickle Cell Disease

3. Sickle cell disease: when and how to transfuse

4. Low hemoglobin increases risk for cerebrovascular disease, kidney disease, pulmonary vasculopathy, and mortality in sickle cell disease: A systematic literature review and meta-analysis

5. Intravascular hemolysis and the pathophysiology of sickle cell disease

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Automated red blood cell exchange with a post‐procedure haematocrit targeted at 34% in the chronic management of sickle cell disease;British Journal of Haematology;2024-07-30

2. Assessing and Evaluating HbS Concentration in Asymptomatic Sickle Cell Patients and Patients With Sickle Cell Crisis Through High-Performance Liquid Chromatography (HPLC) in a Tertiary Hospital in Central India;Cureus;2024-07-21

3. A Case Report of Hyperhemolytic Syndrome in Sickle Cell Disease, with a Special Focus on Avoiding the Use of Transfusions;Thalassemia Reports;2024-03-04

4. One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study;Blood Advances;2023-12-15

5. Impact and burden of sickle cell disease in critically ill obstetric patients in a high dependency unit in Sierra Leone—a registry based evaluation;BMC Pregnancy and Childbirth;2023-08-12